SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Torrent Pharmaceuticals slips on reporting 21% fall in Q3 consolidated net profit

06 Feb 2017 Evaluate

Torrent Pharmaceuticals is currently trading at Rs 1284.00, down by 31.20 points or 2.37% from its previous closing of Rs. 1315.20 on the BSE.

The scrip opened at Rs. 1320.55 and has touched a high and low of Rs. 1324.00 and Rs. 1276.00 respectively. So far 20015 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1767.80 on 25-Aug-2016 and a 52 week low of Rs. 1185.60 on 09-Nov-2016.

Last one week high and low of the scrip stood at Rs. 1358.95 and Rs. 1266.05 respectively. The current market cap of the company is Rs. 21745.12 crore.

The promoters holding in the company stood at 71.25%, while Institutions and Non-Institutions held 17.76% and 10.99% respectively.

Torrent Pharmaceuticals has reported over two fold rise in its net profit at Rs 234 crore for the quarter ended December 31, 2016 as compared to Rs 96 crore for the same quarter in the previous year. Total income of the company increased by 20.66% at Rs 1320 crore for the quarter under review as compared Rs 1094 crore for the corresponding quarter previous year. 

On the consolidated basis, the company has reported 21.03% fall in its net profit after taxes, minority interest and share of profit/(loss) of associates at Rs 229 crore for the quarter ended December 31, 2016, as compared to Rs 290 crore for the same quarter in the previous year. Total income of the company decreased by 6.51% at Rs 1493 crore for the quarter under review as compared Rs 1597 crore for the corresponding quarter previous year.  

Torrent Pharma Share Price

4178.85 22.50 (0.54%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×